Literature DB >> 3773200

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

W P Castelli, R J Garrison, P W Wilson, R D Abbott, S Kalousdian, W B Kannel.   

Abstract

The first report from the Framingham Study that demonstrated an inverse relationship between high-density lipoprotein cholesterol (HDL-C) and the incidence of coronary heart disease (CHD) was based on four years of surveillance. These participants, aged 49 to 82 years, have now been followed up for 12 years, and this report shows that the relationship between the fasting HDL-C level and subsequent incidence of CHD does not diminish appreciably with time. Since a second measurement of HDL-C is available eight years after the initial determination, the relationship of HDL-C measurements on the same subjects at two points in time is examined. This second HDL-C measurement is also used in a multivariate model that includes cigarette smoking, relative weight, alcohol consumption, casual blood glucose, total cholesterol, and blood pressure. It is concluded that even after these adjustments, nonfasting HDL-C and total cholesterol levels are related to development of CHD in both men and women aged 49 years and older. Study participants at the 80th percentile of HDL-C were found to have half the risk of CHD developing when compared with subjects at the 20th percentile of HDL-C.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3773200

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  413 in total

1.  Effect of postmenopausal hormone replacement therapy on lipoprotein and homocysteine levels in Chinese women.

Authors:  R Y Man; L K Ting; S Fan; M M Lau; Y L Siow; Y H Chung; K O
Journal:  Mol Cell Biochem       Date:  2001-09       Impact factor: 3.396

2.  Molecular belt models for the apolipoprotein A-I Paris and Milano mutations.

Authors:  A E Klon; M K Jones; J P Segrest; S C Harvey
Journal:  Biophys J       Date:  2000-09       Impact factor: 4.033

Review 3.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 4.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

5.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.

Authors:  J G Fodor; J J Frohlich; J J Genest; P R McPherson
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

6.  Lifestyle change and high-density lipoprotein change: the US Department of Veterans Affairs Normative Aging Study.

Authors:  Catherine Rahilly-Tierney; Pantel Vokonas; J Michael Gaziano; Avron Spiro
Journal:  Clin Cardiol       Date:  2012-03-08       Impact factor: 2.882

Review 7.  The insulin resistance syndrome.

Authors:  Gerald M Reaven
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

8.  Dietary and pharmacologic management of cholesterol.

Authors:  B M Rifkind
Journal:  Tex Heart Inst J       Date:  1990

9.  Is good cholesterol always good?

Authors:  Gilbert R Thompson
Journal:  BMJ       Date:  2004-08-28

10.  Association between carbohydrate intake and serum lipids.

Authors:  Yunsheng Ma; Youfu Li; David E Chiriboga; Barbara C Olendzki; James R Hebert; Wenjun Li; Katherine Leung; Andrea R Hafner; Ira S Ockene
Journal:  J Am Coll Nutr       Date:  2006-04       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.